S. Venkat Rao, CEO and whole time Director of Vanta Bioscience Limited shared that this is in continuation to earlier announcement to capitalise the new business opportunity in the field of Clinical Research services. This Subsidiary will carry out the business of Clinical research i.e. bio-equivalence, bio-analytical studies, clinical trials, pharmacovigilance, medical writing etc. Going forward, Vanta Clinical Research Limited is expected to be Company’s biggest money spinner and is expected to add Rs250 crores to Company’s top line by year 2024-25, through organic and inorganic means
The Company has already appointed Promotor Director to head this subsidiary. He has more than three decades of experience in Clinical Research having set up similar facilities for some of the industry majors. The new subsidiary is likely to start contributing to top line during the last quarter of current financial year.
The Board of Directors was also apprised that Company’s growth plan also included proposing to set up a full-fledged Analytical Services as a separate vertical within the Company. The Analytical Services are also expected contribute significantly to the revenues of the Company in near future.